Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical senior executive Iman Jeddi exercised stock options and sold shares in a routine, pre-planned transaction. On the same day, he exercised 5,625 non-qualified stock options at $76.9989 per share and sold 5,625 common shares at $420.55 per share under a Rule 10b5-1 trading plan. After these transactions, he holds 6,463 common shares directly and 26,649 common shares indirectly through a trust.
Intuitive Surgical, Inc. has announced an internal leadership change in its commercial organization. Taylor Patton, currently Global Senior Vice President of the company’s endoluminal business, will become Chief Commercial and Marketing Officer effective July 1, 2026 and join the Executive Leadership team.
Current Chief Commercial and Marketing Officer Henry L. Charlton will transition to Senior Vice President of Global Business Operations on the same date. The company highlights Patton’s nearly two decades of experience across its da Vinci, Ion and Digital platforms and notes that Charlton will work closely with Patton to support a smooth transition in global commercial and customer-support activities.
Intuitive Surgical executive Mark Brosius reported small open-market sales of company stock under a pre-set trading plan. The EVP & Chief Manufacturing and Supply Chain sold 18 shares of Common Stock on May 21, 2026 at $446.04 per share and another 18 shares on May 22, 2026 at $439.80 per share. These transactions were carried out pursuant to a Rule 10b5-1 Trading Plan that expires on February 14, 2027. After these sales, Brosius directly holds 1,523 shares of Intuitive Surgical Common Stock.
Intuitive Surgical EVP & Chief Manufacturing and Supply Chain officer Mark Brosius reported small open-market sales of company common stock. Over three days, he sold 18 shares on each of May 18, May 19, and May 20, 2026 at prices of $422.47, $440.70, and $440.38 per share.
After these sales totaling 54 shares, Brosius directly holds 1,559 shares of Intuitive Surgical common stock. The filing notes that the transactions were executed under a pre-arranged Trading Plan that complies with SEC Rule 10b5-1 and runs through February 14, 2027, indicating they were scheduled in advance rather than discretionary trades.
INTUITIVE SURGICAL INC executive Gary Loeb, EVP & Chief Legal and Compliance, reported an open-market sale of 400 shares of Common Stock at $446.95 per share. The transaction was executed under a Rule 10b5-1 trading plan that expires on January 29, 2027. Following this sale, he directly holds 6,120 shares of the company’s stock.
Intuitive Surgical, Inc. increased the authorized amount under its common stock repurchase program to an aggregate $5.0 billion, to be funded with cash, cash equivalents, and investments. Repurchases may occur over time through open-market and other transactions and may be suspended or discontinued at any time.
At its April 30, 2026 annual meeting, stockholders elected ten directors, approved on an advisory basis the compensation of named executive officers, ratified PricewaterhouseCoopers LLP as auditor for the year ending December 31, 2026, and approved an amendment and restatement of the 2010 Incentive Award Plan.
The amended plan increases shares reserved for awards from 120,350,000 to 125,350,000, extends the plan term to January 29, 2036, and further specifies how awards are treated in a change in control.
GUTHART GARY S reported acquisition or exercise transactions in this Form 4 filing.
Intuitive Surgical Inc. director Gary S. Guthart received a grant of 554 restricted stock units tied to the company’s common stock. These RSUs were awarded at no cash cost per unit and represent a stock-based compensation award rather than an open-market purchase.
According to the terms, 100% of the RSUs will vest on the earlier of the one-year anniversary of the grant date or the next Annual Meeting of Stockholders, subject to his continued service. After this grant, the reported holding for this RSU award is 554 units.
INTUITIVE SURGICAL INC director Monica P. Reed reported routine equity compensation activity. On April 30, 2026, she exercised 531 shares of restricted stock units into the same number of common shares, bringing her direct common stock holdings to 2,876 shares.
On the same date, she received a new grant of 554 restricted stock units. According to the disclosure, 100% of these RSUs will vest on the earlier of the one-year anniversary of the grant date or the next Annual Meeting of Stockholders, subject to her continued service.